Glaucoma
DMEK Outcomes after Glaucoma Surgery
What accounts for problems in these cases? Howard Larkin reports from the 2022 ASCRS Annual Meeting.
Howard Larkin
Published: Friday, August 5, 2022
Rebubbling, primary graft failure, and endothelial cell loss rates all appeared to trend higher in a recent review of Descemet membrane endothelial keratoplasty (DMEK) performed after tube or trabeculectomy surgery, reported Mark A Terry MD at the 2022 ASCRS Annual Meeting.
In a study of 1,501 consecutive DMEK cases, the 25 performed after trabeculectomy or filtration tube surgery for glaucoma experienced more complications than those without previous glaucoma filtration surgery. But while the differences were notable, they did not rise to statistical significance, possibly due to the small post-glaucoma sample size.
One thing previous glaucoma surgery did not affect was unscrolling time during DMEK, Dr Terry said. Mean unscroll time in the post-glaucoma surgery group was 2.9±3.0 minutes compared with 3.4±5.2 minutes for the control group (p=0.53), indicating the DMEK surgery in post-glaucoma eyes was generally not any more difficult than in Fuchs’ dystrophy eyes.
Rebubbling rates were higher for the post-glaucoma group at 24% compared with 13% for the control group (p=0.11). Primary graft failure rates were 4% for the post-glaucoma surgery group compared with 1.4% for the control group (p=0.28). Endothelial cell loss three to six months after surgery came closest to statistical significance at 39.1% for the post-glaucoma surgery group and 30.4% for the control group (p=0.09).
Dr Terry’s rebubble rates are consistent with studies of postglaucoma surgery DMEK in the literature, while his endothelial cell loss and graft failure rates were about half that of other studies. They include a 2019 study finding a 22% rebubble rate, 71% endothelial cell loss, and 9% primary graft failure rate one year after DMEK in 23 patients with glaucoma drainage devices.i
“These cell loss and failure rates are high,” he said.
Another study reviewed 51 post-glaucoma surgery DMEK cases and found lower graft survival rates and higher endothelial cell loss rates at 12, 24, 36, and 48 months after DMEK compared with controls without previous glaucoma surgery.ii In a third study, 27 eyes with DMEK after a glaucoma drainage device also had lower graft survival rates and higher endothelial cell loss than 39 eyes with DMEK after trabeculectomy.iii
INFLAMMATION AND REDUCED AQUEOUS MAY PLAY A ROLE
Dr Terry discussed several possible reasons for the higher rates of rebubbling, primary graft failure, and endothelial cell loss for DMEK after glaucoma surgery. Rebubbling rates may be higher due to more frequent hypotony and loss of bubble support due to gas moving up the tube or bleb. Chronic inflammation and reduced aqueous nutritional support may also be factors affecting graft failure and endothelial cell loss.
i American Journal of Ophthalmology. 2019; 199: 150–158.
ii American Journal of Ophthalmology. 2020; 218: 7–16.
iii Graefe’s Archive for Clinical and Experimental Ophthalmology. 2022 May; 260(5): 1573–1582.
Mark A Terry MD is Director of Corneal Services at Devers Eye Institute and Professor of Clinical Ophthalmology at Oregon Health & Science University in Portland, Oregon, USA. mterry@deverseye.org
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Piecing Together a Solution
What is the best use of robotics and AI in cataract and refractive surgery?
Advances in Toric IOL Alignment
Biomorphometric approaches offer high precision and increase efficiency.
Library of Short Videos Complements Educational Offerings
Tackling Waste in Retinal Surgery
Reducing waste from intravitreal injections is an achievable goal.
The Modern Era of Refractive Surgery
New technologies for screening and treatment qualify more patients for intervention.
Monofocal Plus Finding the Balance
Enhanced monofocals may be the future standard of care in cataract patients.
Growing Options Optimise Outcomes in Cataract Surgery
Understanding the promise and potential problems of AI-based IOL formulas.